Diabetes is a common risk factor for cardiovascular disease. Coronary heart disease and left ventricular dysfunction are more common in diabetic patients than in non-diabetic patients, and diabetic patients benefit less from revascularisation procedures. This increased risk can only partly be explained by the adverse effects of diabetes on established risk factors; hence, a substantial part of the excess risk must be attributable to direct effects of hyperglycaemia and diabetes. In type 2 diabetes, hyperinsulinaemia, insulin resistance and hyperglycaemia have a number of potential adverse effects, including effects on endothelial function and coagulation. Risk factor modification has been shown to reduce the occurrence of cardiovascular events in patients with diabetes; indeed, diabetic patients appear to benefit more in absolute terms than non-diabetic patients. There is thus a strong case for intensive treatment of risk factors, including insulin resistance and hyperglycaemia, in patients with type 2 diabetes.
Pan W.-H, Cedres LB, Liu K. et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol1986;123:504-16.
2.
Reunanen A.Diabetes as a risk factor for coronary heart disease. In: Oliver MF, Vedin A, Wilhelmsson C (eds.). Myocardial infarction in women. Edinburgh: Churchill Livingstone, 1986.
3.
Stamler J., Vaccaro O., Neaton JD, Wentworth D.Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993;16:434-44.
4.
Kuller LH, Velentgas P., Barzilay J. et al. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol2000;20:823-9.
5.
Hayden JM, Reaven PDCardiovascular disease in diabetes mellitus Type 2: a potential role for novel cardiovascular risk factors. Curr Opin Lipidol2000;11:519-28.
Hauner H.Occurrence of diabetes mellitus in Germany [in German]. Dtsch Med Wochenschr1998;123:777-82.
8.
Tenerz Å. , Lonnberg I., Berne C., Nilsson G., Leppert J.Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes?Eur Heart J2001;22:1102-10.
9.
www.chd-taskforce.de. Accessed September 17, 2001.
10.
Claudi T., Midthjell K., Holmen J., Fougner K., Krüger Ø, Wiseth W.Cardiovascular disease and risk factors in persons with Type 2 diabetes diagnosed in a large population screening. The Nord-Trøndelag Diabetes Study, Norway . J Intern Med2000;248:492-500.
11.
Chen W., Bao W., Begum S., Elkasabany A., Srinivasan SR, Berenson GSAge-related patterns of the clustering of cardiovascular risk variables of Syndrome X from childhood to young adulthood in a population made up of black and white subjects. The Bogalusa Heart Study. Diabetes2000;49:1042-8.
12.
Haffner SM, Lehto S., Ronnemaa T., Pyörälä K., Laakso M.Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998;339:229-34.
13.
Herlitz J., Malmberg K., Karlson BW, Rydén L., Hjalmarson Å. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand1988;224:31-8.
14.
The BARI Investigators.Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation1997;96:1761-9.
15.
Hasdai D., Granger CB, Srivatsa SS et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes . J Am Coll Cardiol2000;35:1513-5.
16.
McGuire DK, Emanuelsson H., Granger CB et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. Eur Heart J2000;21:1750-8.
17.
Waldecker B. , Waas W., Haberbosch W. et al. Type 2 diabetes and acute myocardial infarction. Angiographic findings and results of an invasive therapeutic approach in Type 2 diabetic versus nondiabetic patients. Diabetes Care1999;22:1832-8.
18.
Stein B., Weintraub WS, Gebhart SP et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation1995;91:979-89.
19.
Kip KE, Faxon DP, Detre KM, Yeh W., Kelsey SF, Currier JWCoronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry . Circulation1996;94:1818-25.
20.
Abizaid A., Kornowski R., Mintz GS et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol1998;32:584-9.
21.
Elezi S., Kastrati A., Pache J. et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol1998;32:1866-73.
22.
Barsness GW , Peterson ED, Ohman EM et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation1997;96:2551-6.
23.
Elezi S., Kastrati A., Neumann FJ, Hadamitzky M., Dirschinger J., Schomig A.Vessel size and long-term outcome after coronary stent placement. Circulation1998;98:1875-80.
24.
Kastrati A. , Schomig A., Elezi S. et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol1997;30:1428-36.
25.
Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DSRestenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus . Ann Intern Med1993;118:344-9.
26.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
27.
Pyörälä K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G.Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997; 20:614-20.
28.
Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998 ;351:1755-62.
29.
Goldberg RB , Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation1998;98: 2513-9.
Kemnitz JP, Elson DF, Roecker EB et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes1994;43: 204-11.
32.
Nolan JJ, Ludvik B., Beerdsen P. et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med1994;331:1188-93.
33.
Maggs DG, Buchanan TA, Burant CF et al. Metabolic effects of troglitazone monotherapy in Type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med1998;128:176-85.
34.
Mykkänen L.Prevention of coronary heart disease in Type 2 diabetes. Int J Clin Pract2000;suppl13:40-5.
35.
Koshiyama H. , Shimono D., Kuwamura N., Minamikawa J., Nakamura Y.Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J Clin Endocr Metab2001;86:3452-6.
36.
Haffner SM, Greenberg A., Weston W. et al. Effects of rosiglitazone treatment on levels of C-reactive protein and MMP9 in patients with type 2 diabetes. American Heart Association Scientific Sessions; November 11-14, 2001; Anaheim, California. Poster 44, Abstract 565.
37.
Lazar MAProgress in cardiovascular biology: PPAR for the course. Nature Medicine2001;7:23-4.
